Skip to content
Peptide research

ARA-290

Also known as Cibinetide
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

An erythropoietin-derived peptide engineered to spur nerve and tissue repair without raising red blood cell counts, marketed for neuropathic pain and diabetic metabolic support. Evidence rests on Phase 2 trials showing gains in nerve density, pain, and HbA1c, but no Phase 3 data exists and long-term safety is unknown. One trial had serious adverse events including an unrelated death, and non-trial supply is unregulated. Not FDA-approved; banned by WADA.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide designed to mimic the tissue-protective effects of erythropoietin (EPO) — the hormone known for boosting red blood cell production — without actually affecting blood cell counts. It selectively activates a repair receptor found on nerve cells, blood vessel cells, and immune cells, promoting tissue protection, reducing inflammation, and stimulating nerve fiber regeneration. Developed by Araim Pharmaceuticals, it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-related nerve damage.

How it works in the body

Binds to a special receptor formed when the erythropoietin receptor pairs with the beta common receptor (IRR). This triggers anti-inflammatory and tissue-protective signaling in nerves and tissues without stimulating red blood cell production, making it distinct from EPO.

Research overview

ARA-290 works by activating the innate repair receptor (IRR), triggering protective and regenerative responses in damaged tissues — particularly small nerve fibers. In a Phase 2b study of 64 sarcoidosis patients, the optimal dose (4 mg daily for 28 days) produced a 23% increase in corneal nerve fiber area, a direct measure of small nerve regeneration. In a separate trial with 48 type 2 diabetes patients, the same dose significantly improved blood sugar control (HbA1c), neuropathic pain scores, and cholesterol levels. It also blocks TRPV1 pain receptors, contributing to its pain-relieving effects. The compound has received multiple regulatory designations including US and EU Orphan Drug status for sarcoidosis and FDA Fast Track for sarcoidosis-related small fiber neuropathy. Araim Pharmaceuticals has completed an end-of-Phase 2 FDA meeting and has indicated plans for Phase 3 trials. Evidence quality is moderate — multiple small Phase 2 trials show consistent benefits, but large Phase 3 confirmatory trials have not yet been completed.

Who researches ARA-290?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(8)

Rated by level of concern

  • Not approved by any regulatory agency — quality and purity of non-clinical-trial sources cannot be guaranteed

    High

    EMA orphan designation register EU/3/16/1721 (designation only); no FDA/EMA marketing authorization on record

  • Prohibited by WADA — use may result in anti-doping violations for competitive athletes

    High

    WADA World Anti-Doping Code International Standard Prohibited List, section S2.1 (innate repair receptor agonists) — https://www.wada-ama.org/en/prohibited-list

  • Investigational compound — long-term safety profile not established; no Phase 3 data available

    High

    PMID 28475703; PMID 25387363; PMID 24136731; PMID 23168581; PMID 32674280 (Phase 1/2 reports)

  • Serious adverse events in Phase 2 diabetes trial: 4 SAEs including 1 renal insufficiency event (possibly related) and 1 fatal myocardial infarction (judged unrelated by safety committee)

    Moderate

    PMID 25387363 (Mol Med 2015, safety section)

  • No long-term carcinogenicity or reproductive toxicity data available

    Moderate

    Exclusion criteria in PMID 24136731 and PMID 25387363; absence of any published tox study in PubMed

  • Potential immune modulation effects — caution advised when combining with immunosuppressants or biologic anti-inflammatory drugs

    Theoretical

    PMID 24136731 (exclusion criteria); PMID 25728128 (IRR biology review)

  • Injection site reactions (mild) reported in clinical trials

    Theoretical

    PMID 24136731 (safety section, explicitly reports absence of injection-site pain or irritation); PMID 25387363

  • Headache reported as a common mild adverse event

    Theoretical

    No primary source itemizing headache; PMID 24136731 and PMID 25387363 AE reporting reviewed and do not support it

Interaction summary(8)

Rated by direction with this peptide

  • Loop diuretics (furosemide) and other agents in patients with pre-existing renal impairment

    CautionLow

    Severity reduced from Moderate: this rests on a single confounded case. In the Phase 2 diabetes trial, one subject whose furosemide dose was increased mid-trial had borderline renal insufficiency worsen (creatinine ~119 to ~159 umol/L) without recovery after ARA-290 was stopped while furosemide continued — a pattern at least as consistent with diuretic-driven prerenal decline as with study drug. No pharmacokinetic or interaction study exists. It is the only renal signal in the entire human record, so it justifies renal monitoring when baseline function is borderline, but it does not support asserting a moderate-severity interaction.

    PMID 25387363 (Mol Med 2015, safety section)

  • Insulin, sulfonylureas and other glucose-lowering agents

    CautionLow

    ARA-290 produced a small placebo-controlled HbA1c reduction (-0.21% at day 56, P=0.002) that persisted about a month after dosing stopped, so additive glucose lowering on top of an intensive regimen is mechanistically plausible and periodic glucose monitoring is reasonable. The effect is very small, it comes from one unreplicated Phase 2 trial, and no hypoglycemia signal was reported even though subjects continued their full diabetes regimens throughout.

    PMID 25387363

  • Erythropoiesis-stimulating agents (epoetin, darbepoetin, CERA)

    NeutralTheoretical

    ARA-290 acts at the EPOR-betacommon innate repair receptor rather than the EPOR homodimer, and human trials showed no clinically significant hematologic change and no anti-drug antibodies, so no additive erythropoietic or thrombotic interaction is expected on mechanism. The two have never been co-administered in any study, so this is expectation rather than evidence. Both fall within the same WADA prohibited class.

    PMID 25387363; PMID 24136731; PMID 25728128

  • Neuropathic pain medications (opioids, gabapentinoids, tricyclics, SNRIs, NSAIDs, antiepileptics)

    NeutralLow

    In the Phase 2 diabetes RCT subjects remained on a wide range of these agents throughout dosing and follow-up with no reported interaction, so concurrent use is the studied condition rather than an untested one — ARA-290 was evaluated as an add-on, never as a replacement. No formal interaction study was performed, and concomitant-medication tolerance in a small trial is weak evidence of safety, not proof of none.

    PMID 25387363 (concomitant medication reporting)

  • Systemic corticosteroids and conventional immunosuppressants (in sarcoidosis)

    NeutralLow

    Sarcoidosis patients on stable background immunosuppression were enrolled and treated in the ARA-290 trials without reported interaction or loss of effect, which is consistent with the mechanistic claim that IRR agonism is tissue-protective rather than immunosuppressive. No formal interaction study exists and the numbers involved are small.

    PMID 24136731; PMID 23168581

  • Anti-TNF biologics (infliximab, adalimumab, etanercept)

    CautionTheoretical

    There is no interaction data at all: the sarcoidosis trials excluded anyone who had received anti-TNF therapy in the preceding months, so combined use is simply unstudied. The exclusion itself signals investigator caution about overlapping anti-inflammatory pathways, but no clinical consequence has ever been demonstrated in either direction.

    PMID 24136731 (exclusion criteria)

  • Statins and other lipid-lowering therapy

    NeutralTheoretical

    'synergistic' asserts a combination effect that has never been tested. What actually exists: in one small Phase 2 trial, ARA-290 improved the cholesterol/HDL ratio (P=0.039) and triglycerides (P=0.043) as secondary endpoints while patients remained on their existing regimens, which shows only that the lipid change was observed on a statin background, not that the two act additively or synergistically. No adverse interaction is expected or reported either.

    PMID 25387363

  • Vaccination / recent immunization

    CautionTheoretical

    The sarcoidosis trial protocol excluded subjects vaccinated or immunized within the preceding months, so the effect of IRR agonism on vaccine-induced immune responses is entirely unstudied. No clinical consequence has been demonstrated in either direction; this is an unstudied combination, not an observed risk.

    PMID 24136731 (exclusion criteria)

Known risks(8)

  • Investigational compound — long-term safety profile not established; no Phase 3 data available

  • Injection site reactions (mild) reported in clinical trials

  • Headache reported as a common mild adverse event

  • Serious adverse events in Phase 2 diabetes trial: 4 SAEs including 1 renal insufficiency event (possibly related) and 1 fatal myocardial infarction (judged unrelated by safety committee)

  • Potential immune modulation effects — caution advised when combining with immunosuppressants or biologic anti-inflammatory drugs

  • No long-term carcinogenicity or reproductive toxicity data available

  • Not approved by any regulatory agency — quality and purity of non-clinical-trial sources cannot be guaranteed

  • Prohibited by WADA — use may result in anti-doping violations for competitive athletes

Drug interactions(5)

  • Immunosuppressants (e.g., methotrexate, cyclosporine, tacrolimus)

    Moderate — use with caution under medical supervision

    Potential amplification of immune modulation; ARA-290 has anti-inflammatory properties that may compound with immunosuppressive effects

  • Biologic anti-inflammatory agents (e.g., TNF inhibitors, IL-6 inhibitors)

    Moderate — caution advised; no formal interaction studies conducted

    Overlapping anti-inflammatory mechanisms may increase risk of infection or excessive immune suppression

  • Erythropoiesis-stimulating agents (EPO, darbepoetin)

    Low — theoretical concern; ARA-290 does not have erythropoietic activity

    Theoretical competition for EPO receptor binding sites on the innate repair receptor complex; clinical significance unknown

  • TRPV1 agonists (e.g., capsaicin topical preparations)

    Low — pharmacodynamic interaction; clinical relevance not established

    ARA-290 antagonizes TRPV1; concurrent TRPV1 agonist use may reduce efficacy of either compound

  • Nephrotoxic drugs (e.g., NSAIDs, aminoglycosides)

    Moderate — monitor renal function

    One case of renal insufficiency was reported in a patient on furosemide during ARA-290 treatment; exercise caution with nephrotoxic combinations

Research & benefits

Evidence base

Evidence Level
Early Clinical (Phase I/II)
Total Studies
15
Human Studies
6

Researched for(8)

Rated by confidence in the evidence

  • Regenerates small nerve fibers, shown as increased corneal nerve fiber area in a Phase 2 trial

    Medium

    Small placebo-controlled trial found increased corneal nerve fiber area at 4 mg dose in sarcoidosis patients.

    PMID 28475703 (Invest Ophthalmol Vis Sci 2017) is the primary source: a placebo-controlled Phase 2b trial in sarcoidosis-associated small nerve fiber neuropathy showing a significant placebo-corrected increase in corneal nerve fiber area of 697 um2 at the 4 mg dose (p=0.012); this is the only dose that reached significance. PMID 24136731 (Mol Med 2013) is an earlier open-label pilot in the same population and same peptide showing a corroborating 14.5% increase from baseline.

  • Reduces neuropathic pain — significant improvements in PainDetect and SFNSL scores in both sarcoidosis and diabetic neuropathy patients

    Medium

    Human trials show pain score gains, but the largest trial's effect missed significance.

    PMID 25387363; PMID 24136731; PMID 23168581; PMID 28475703

  • Improves metabolic control — significant reductions in HbA1c (p=0.002), cholesterol/HDL ratio (p=0.039), and triglycerides (p=0.043) in diabetic patients

    Medium

    Single small trial found improved HbA1c, cholesterol ratio, and triglycerides in diabetics.

    PMID 25387363 (Mol Med 2015)

  • Anti-inflammatory effects without immunosuppression — reduces pro-inflammatory cytokine signaling via innate repair receptor activation

    Low

    Mechanism and animal data only, no human trial has shown reduced inflammatory markers.

    PMID 25728128 (Brines & Cerami, Pharmacol Ther 2015); PMID 25387363

  • Tissue cytoprotection — activates endogenous repair pathways through the innate repair receptor (IRR) on endothelial cells, glia, and immune cells

    Low

    Extensive animal data across injury models, no human tissue-protection endpoint tested.

    PMID 25728128 (Pharmacol Ther 2015); preclinical models cited within PMID 25387363

  • No erythropoietic activity — engineered to avoid EPO-related risks (polycythemia, hypertension, thrombosis)

    High

    Multiple human RCTs found no erythropoietic changes over 28 days of dosing.

    PMID 25387363; PMID 24136731; PMID 23168581; PMID 32674280 (A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema, J Clin Med 2020)

  • Improves quality of life — significant improvements in physical role functioning (p=0.05) and vitality (p=0.02) on RAND-36/SF-36

    Low

    Uncontrolled within-group score changes, not tested against placebo directly.

    PMID 25387363 (RAND-36 data); PMID 23168581 (SF-36 subdomains)

  • Potential pancreatic islet graft protection — EU orphan designation for prevention of graft loss in islet transplantation

    Speculative

    EU orphan designation granted, based on preclinical islet studies, no human efficacy data.

    EMA orphan designation register, EU/3/16/1721 (https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721)

Benefits(8)

  • Regenerates small nerve fibers, shown as increased corneal nerve fiber area in a Phase 2 trial

  • Reduces neuropathic pain — significant improvements in PainDetect and SFNSL scores in both sarcoidosis and diabetic neuropathy patients

  • Improves metabolic control — significant reductions in HbA1c (p=0.002), cholesterol/HDL ratio (p=0.039), and triglycerides (p=0.043) in diabetic patients

  • Anti-inflammatory effects without immunosuppression — reduces pro-inflammatory cytokine signaling via innate repair receptor activation

  • Tissue cytoprotection — activates endogenous repair pathways through the innate repair receptor (IRR) on endothelial cells, glia, and immune cells

  • No erythropoietic activity — engineered to avoid EPO-related risks (polycythemia, hypertension, thrombosis)

  • Improves quality of life — significant improvements in physical role functioning (p=0.05) and vitality (p=0.02) on RAND-36/SF-36

  • Potential pancreatic islet graft protection — EU orphan designation for prevention of graft loss in islet transplantation

Key studies(5)

  1. Heij L, Niesters M, Swartjes M, et al.

    Molecular Medicine

    2012

    ARA-290 significantly reduced neuropathic symptoms in sarcoidosis patients (SFNSL -11.5 vs -2.9, p<0.05) with no safety concerns

  2. Brines M, et al.

    Molecular Medicine

    2015

    ARA-290 (4 mg SC daily x28 days) significantly improved HbA1c (p=0.002), neuropathic pain (p=0.037), and corneal nerve fiber density (p=0.02) in type 2 diabetes patients

  3. Culver DA, Dahan A, Bajorunas D, et al.

    Investigative Ophthalmology & Visual Science (IOVS)

    2017

    Phase 2b: 4 mg cibinetide SC daily for 28 days produced ~23% increase in corneal nerve fiber area in 64 sarcoidosis patients

  4. Zhang W, Yu G, Zhang M.

    Peptides

    2016

    Demonstrated that ARA-290 antagonizes TRPV1 channels, providing both disease-modifying and analgesic mechanisms

  5. Araim Pharmaceuticals

    2014

    Phase 2b trial registration for dose-ranging study in sarcoidosis-associated small fiber neuropathy

Regulation & availability

Why researchers look at it

In a Phase 2b trial of 64 sarcoidosis patients, the optimal dose produced a 23% increase in corneal nerve fiber area — one of the few demonstrated cases of actual nerve regeneration in a clinical setting. A separate trial in 48 type 2 diabetes patients showed significant improvements in HbA1c, neuropathic pain, and cholesterol. The FDA has granted Fast Track and Orphan Drug designations, and if Phase 3 confirms Phase 2 results, ARA-290 could become the first therapy specifically approved for small fiber neuropathy.

Estimated cost
Not yet available — investigational
FDA status
Investigational New Drug (IND). Not FDA-approved for any indication. Has received: (1) FDA Orphan Drug Designation for treatment of sarcoidosis (2016); (2) FDA Fast Track Designation for sarcoidosis-associated small fiber neuropathy (2014); (3) FDA Orphan Drug Designation for pancreatic islet transplantation graft survival; (4) EU Orphan Medicinal Product designations for sarcoidosis and pancreatic islet transplantation. Completed end-of-Phase 2 FDA meeting with plans for Phase 3 development.
WADA status
Prohibited — ARA-290 is banned by the World Anti-Doping Agency (WADA) under substances related to EPO-derived peptides with tissue-repair and potential performance-enhancing properties. Athletes subject to anti-doping regulations must not use this compound.
Prescribability
ARA-290 is not FDA-approved and is not eligible for compounding: FDA found that its nomination for the compounding list lacked adequate support (Category 3). Clinical use requires an authorized investigational pathway.
Availability
Not commercially available as an approved pharmaceutical. Available through clinical trials conducted by Araim Pharmaceuticals; human use remains investigational. Its current 503A Category 3 listing does not provide a routine compounding pathway, and physician supervision does not change that status. Not available as a standard prescription medication.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(10)

  1. 2012
    Phase 2 pilot study completed — ARA-290 (2 mg IV 3x/week) in sarcoidosis SFN (n=22); published in Molecular Medicine
  2. 2014
    Phase 2 trial in type 2 diabetes (NTR3858) completed — ARA-290 (4 mg SC daily x28 days, n=48)
  3. 2014
    FDA Fast Track Designation granted for sarcoidosis-associated small fiber neuropathy
  4. 2014
    Phase 2 diabetes trial results published in Molecular Medicine (Brines et al.)
  5. 2016
    FDA Orphan Drug Designation granted for treatment of sarcoidosis
  6. 2016
    EU Orphan Medicinal Product designation granted for prevention of graft loss in pancreatic islet transplantation
  7. 2016
    FDA Orphan Drug Designation granted for pancreatic islet transplantation graft survival
  8. 2017
    Phase 2b dose-ranging study (1, 4, 8 mg SC daily, n=64) results published; 4 mg identified as optimal dose
  9. 2017
    End-of-Phase 2 meeting completed with FDA; Phase 3 development plans announced for sarcoidosis neuropathy and diabetic neuropathy
  10. 2026 (current)
    No Phase 3 trial results publicly reported; ARA-290 remains investigational with no marketing approval in any jurisdiction

Sources & FAQs

Research sources(10)

Frequently asked questions(6)

What is ARA-290 and how does it differ from EPO?

ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the tissue-protective region of erythropoietin (EPO). Unlike EPO, it does not stimulate red blood cell production, avoiding risks of polycythemia, hypertension, and thrombosis. It selectively activates the innate repair receptor (IRR) for tissue protection and repair.

What conditions is ARA-290 being studied for?

Primary clinical development targets sarcoidosis-associated small fiber neuropathy and diabetic peripheral neuropathy. Preclinical research has also explored applications in pancreatic islet transplantation, chronic pain, wound healing, and neuroinflammation.

How is ARA-290 administered?

In clinical trials, ARA-290 was administered either intravenously (in early studies) or by subcutaneous injection (in later Phase 2 studies).

Is ARA-290 FDA-approved?

No. ARA-290 remains an investigational drug. It has received FDA Orphan Drug and Fast Track designations for sarcoidosis-associated neuropathy, but has not completed Phase 3 trials or received marketing approval in any country.

What are the main side effects?

In clinical trials, ARA-290 was generally well tolerated. Common mild side effects included headache and injection site reactions. No dose-limiting toxicities were observed. One trial reported 4 serious adverse events in the treatment arm, including a fatal MI in a 70-year-old patient judged unrelated to the drug by the safety committee.

Can athletes use ARA-290?

No. ARA-290 is prohibited by the World Anti-Doping Agency (WADA) as it falls under substances with tissue-repair and potentially performance-enhancing properties related to EPO-derived peptides.